© 1996 British Society for Rheumatology
research-article |
TUMOUR NECROSIS FACTOR ALPHA AND ITS SOLUBLE RECEPTORS PARALLEL CLINICAL DISEASE AND AUTOIMMUNE ACTIVITY IN SYSTEMIC LUPUS ERYTHEMATOSUS
,
*2nd Department of Medicine, Lainz Hospital Vienna, Austria
Ludwig Boltzmann-Institute for Rheumatology and Balneology Vienna, Austria
Department of Rheumatology, Clinic for Internal Medicine III, University of Vienna, Vienna, Austria
Correspondence to:
Correspondence to: G. Steiner, Ludwig Boltzmann-Institute for Rheumatology and Balneology, 2nd Department of Medicine, Lainz Hospital, Wolkersbergenstrasse 1, A-1130, Vienna, Austria.
Cytokincs are believed to play an important role in the pathogenesis of systemic lupus erythematosus (SLE). However, for tumour necrosis factor alpha (TNF-
) both beneficial and deleterious effects have been reported. To obtain information about the involvement of this cytokine in the pathophysiology of SLE, serum levels of TNF-, the soluble forms of the 55 and 75 IcDa tumour necrosis factor receptors (TNF-R55 and TNF-R75), and interleukin-6 (IL-6) were measured by ELISA in nine female patients over a period of 2 yr. Compared to healthy controls, levels of TNF- (median 47pg/ml, range < 15-222 pg/ml), TNF-R55 (median 1.9ng/ml, range 0.8–10.8 ng/ml), TNF-R75 (median 4.7 ng/ml, range 1.5–15 ng/ml) and IL-6 (median 3.5 pg/ml, range < 3.5–52 pg/ml) were significantly elevated in SLE patients (P < 0.0001 vs controls in all cases). There were strong correlations between TNF- and its soluble receptors (P < 0.0001). Moreover, TNF- and both TNF-Rs strongly correlated with clinical and serological parameters of disease activity, such as the European Consensus Lupus Activity Measurement (ECLAM) score, anti-dsDNA antibodies, C-reactive protein (CRP), erythrocyte sedimentation rate (ESR) and anaemia (P < 0.0001 for all comparisons). TNF- and TNF-R75 also correlated with IL-6 (P < 0.0001). However, no correlation between IL-6 and ECLAM was found, and the correlation of IL-6 with anti-dsDNA was relatively weak; in contrast, IL-6 correlated strongly with CRP and ESR (P < 0.0001). Although these data do not allow us ultimately to discriminate between beneficial and deleterious effects of TNF-, they nevertheless suggest a central role for the TNF system in the pathophysiology of SLE.
KEY WORDS: SLE, Cytokines, TNF-, TNF receptors, IL-6
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  A. Negron, M. Molina, A. Mayor, V. Rodriguez, and L. Vila Factors associated with metabolic syndrome in patients with systemic lupus erythematosus from Puerto Rico Lupus, April 1, 2008; 17(4): 348 - 354. [Abstract] [PDF]
|
|
|
|
 |
|
 A. M. Bertoli, L. M. Vila, M. Apte, B. J. Fessler, H. M. Bastian, J. D. Reveille, G. S. Alarcon, and for the LUMINA Study Group Systemic lupus erythematosus in a multiethnic US cohort LUMINA LI: Anaemia as a predictor of disease activity and damage accrual Rheumatology, September 1, 2007; 46(9): 1471 - 1476. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A Wozniacka, A Lesiak, J Narbutt, D P McCauliffe, and A Sysa-Jedrzejowska Chloroquine treatment influences proinflammatory cytokine levels in systemic lupus erythematosus patients Lupus, May 1, 2006; 15(5): 268 - 275. [Abstract] [PDF]
|
|
|
|
 |
|
 N J McHugh, P Owen, B Cox, J Dunphy, and K Welsh MHC class II, tumour necrosis factor {alpha}, and lymphotoxin {alpha} gene haplotype associations with serological subsets of systemic lupus erythematosus Ann Rheum Dis, April 1, 2006; 65(4): 488 - 494. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. V. Navarra Immune therapy of lupus: what is on the horizon? Nephrol. Dial. Transplant., March 1, 2006; 21(3): 579 - 581. [Full Text] [PDF]
|
|
|
|
 |
|
 J. J. Alexander, A. Jacob, L. Bao, R. L. Macdonald, and R. J. Quigg Complement-Dependent Apoptosis and Inflammatory Gene Changes in Murine Lupus Cerebritis J. Immunol., December 15, 2005; 175(12): 8312 - 8319. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. A. Schaumberg, R. J. Glynn, A. J. Jenkins, T. J. Lyons, N. Rifai, J. E. Manson, P. M. Ridker, and D. M. Nathan Effect of Intensive Glycemic Control on Levels of Markers of Inflammation in Type 1 Diabetes Mellitus in the Diabetes Control and Complications Trial Circulation, May 17, 2005; 111(19): 2446 - 2453. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J S Smolen, G Steiner, and M Aringer Anti-cytokine therapy in systemic lupus erythematosus Lupus, March 1, 2005; 14(3): 189 - 191. [Abstract] [PDF]
|
|
|
|
|
|
J. Grisar, D. Aletaha, C. W. Steiner, T. Kapral, S. Steiner, D. Seidinger, G. Weigel, I. Schwarzinger, W. Wolozcszuk, G. Steiner, et al. Depletion of Endothelial Progenitor Cells in the Peripheral Blood of Patients With Rheumatoid Arthritis Circulation, January 18, 2005; 111(2): 204 - 211. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M Aringer and J S Smolen Cytokine expression in lupus kidneys Lupus, January 1, 2005; 14(1): 13 - 18. [Abstract] [PDF]
|
|
|
|
|
|
M Aringer and J S Smolen Tumour necrosis factor and other proinflammatory cytokines in systemic lupus erythematosus: a rationale for therapeutic intervention Lupus, May 1, 2004; 13(5): 344 - 347. [Abstract] [PDF]
|
|
|
|
|
|
D. Marshall, J. P. Dangerfield, V. K. Bhatia, K. Y. Larbi, S. Nourshargh, and D. O. Haskard MRL/lpr lupus-prone mice show exaggerated ICAM-1-dependent leucocyte adhesion and transendothelial migration in response to TNF-{alpha} Rheumatology, August 1, 2003; 42(8): 929 - 934. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E Svenungsson, G-Z Fei, K Jensen-Urstad, U de Faire, A Hamsten, and J Frostegard TNF-{alpha}: a link between hypertriglyceridaemia and inflammation in SLE patients with cardiovascular disease Lupus, June 1, 2003; 12(6): 454 - 461. [Abstract] [PDF]
|
|
|
|
|
|
R A Mageed and D A Isenberg Tumour necrosis factor alpha in systemic lupus erythematosus and anti-DNA autoantibody production Lupus, December 1, 2002; 11(12): 850 - 855. [Abstract] [PDF]
|
|
|
|
|
|
M Aringer, E Feierl, G Steiner, G H Stummvoll, E Hofler, C W Steiner, I Radda, J S Smolen, and W B Graninger Increased bioactive TNF in human systemic lupus erythematosus: associations with cell death Lupus, February 1, 2002; 11(2): 102 - 108. [Abstract] [PDF]
|
|
|
|
|
|
M. Aringer, G. H. Stummvoll, G. Steiner, M. Koller, C. W. Steiner, E. Hofler, H. Hiesberger, J. S. Smolen, and W. B. Graninger Serum interleukin-15 is elevated in systemic lupus erythematosus Rheumatology, August 1, 2001; 40(8): 876 - 881. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. A. Limb, R. D. Hollifield, L. Webster, D. G. Charteris, and A. H. Chignell Soluble TNF Receptors in Vitreoretinal Proliferative Disease Invest. Ophthalmol. Vis. Sci., June 1, 2001; 42(7): 1586 - 1591. [Abstract] [Full Text]
|
|
|
|
|
|
R Segal, M Dayan, H Zinger, and E Mozes Suppression of experimental systemic lupus erythematosus (SLE) in mice via TNF inhibition by an anti-TNF{alpha} monoclonal antibody and by pentoxiphylline Lupus, January 1, 2001; 10(1): 23 - 31. [Abstract] [PDF]
|
|
|
|
|
|
I Brink, B Thiele, G-R Burmester, G Trebeljahr, F Emmrich, and F Hiepe Effects of anti-CD4 antibodies on the release of IL-6 and TNF-{alpha} in whole blood samples from patients with systemic lupus erythematosus Lupus, November 1, 1999; 8(9): 723 - 730. [Abstract] [PDF]
|
|
|
|
|
|
J. F. McHale, O. A. Harari, D. Marshall, and D. O. Haskard TNF-{alpha} and IL-1 Sequentially Induce Endothelial ICAM-1 and VCAM-1 Expression in MRL/lpr Lupus-Prone Mice J. Immunol., October 1, 1999; 163(7): 3993 - 4000. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Saito, D. Kobayashi, M. Sasaki, H. Araake, T. Kida, A. Yagihashi, T. Yajima, H. Kameshima, and N. Watanabe Detection of Human Serum Tumor Necrosis Factor-{alpha} in Healthy Donors, Using a Highly Sensitive Immuno-PCR Assay Clin. Chem., May 1, 1999; 45(5): 665 - 669. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R Wu, E Svenungsson, I Gunnarsson, B Andersson, I Lundberg, L S. Elinder, and J Frostegard Antibodies against lysophosphatidylcholine and oxidized LDL in patients with SLE Lupus, February 1, 1999; 8(2): 142 - 150. [Abstract] [PDF]
|
|